VERV vs. ALT, LRMR, KALV, TVTX, OCS, STTK, CMPS, ANL, ABUS, and ATXS
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Altimmune (ALT), Larimar Therapeutics (LRMR), KalVista Pharmaceuticals (KALV), Travere Therapeutics (TVTX), Oculis (OCS), Shattuck Labs (STTK), COMPASS Pathways (CMPS), Adlai Nortye (ANL), Arbutus Biopharma (ABUS), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Verve Therapeutics (NASDAQ:VERV) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
Verve Therapeutics has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
Altimmune received 30 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 69.57% of users gave Altimmune an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
In the previous week, Altimmune had 20 more articles in the media than Verve Therapeutics. MarketBeat recorded 40 mentions for Altimmune and 20 mentions for Verve Therapeutics. Verve Therapeutics' average media sentiment score of 0.57 beat Altimmune's score of 0.18 indicating that Verve Therapeutics is being referred to more favorably in the media.
Verve Therapeutics has a net margin of -1,226.51% compared to Altimmune's net margin of -22,645.37%. Verve Therapeutics' return on equity of -37.35% beat Altimmune's return on equity.
97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 21.4% of Verve Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Verve Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 449.08%. Altimmune has a consensus target price of $17.25, indicating a potential upside of 138.92%. Given Verve Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Verve Therapeutics is more favorable than Altimmune.
Altimmune has lower revenue, but higher earnings than Verve Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Verve Therapeutics beats Altimmune on 12 of the 18 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
